MLH3 Gene Colorectal Cancer Hereditary Nonpolyposis Type 7 NGS Genetic DNA Test
Comprehensive Genetic Screening for Hereditary Colorectal Cancer Risk
The MLH3 Gene Colorectal Cancer Hereditary Nonpolyposis Type 7 NGS Genetic DNA Test represents a breakthrough in personalized cancer risk assessment. This advanced genetic screening specifically targets mutations in the MLH3 gene, which plays a critical role in DNA mismatch repair. When this gene malfunctions, it significantly increases susceptibility to hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome type 7.
Understanding your genetic predisposition to colorectal cancer is essential for early intervention and personalized healthcare planning. Our state-of-the-art Next-Generation Sequencing technology provides unparalleled accuracy in detecting even the most subtle genetic variations that could impact your cancer risk profile.
What This Test Measures and Detects
This comprehensive genetic analysis specifically examines:
- Complete sequencing of the MLH3 gene to identify pathogenic variants
- Detection of single nucleotide polymorphisms (SNPs) associated with increased cancer risk
- Identification of insertion/deletion mutations affecting DNA repair mechanisms
- Assessment of genetic variants linked to hereditary nonpolyposis colorectal cancer type 7
- Comprehensive analysis of DNA mismatch repair pathway integrity
The test utilizes cutting-edge NGS technology that provides superior sensitivity and specificity compared to traditional genetic testing methods, ensuring you receive the most accurate risk assessment available.
Who Should Consider This Genetic Test
Individuals with Specific Risk Factors
This test is particularly recommended for individuals who present with:
- Personal history of colorectal cancer diagnosed before age 50
- Family history of colorectal cancer in multiple generations
- Presence of endometrial, ovarian, gastric, or other Lynch syndrome-associated cancers in the family
- Multiple primary cancers in the same individual
- Known MLH3 gene mutation in family members
- Unexplained early-onset colorectal polyps
- Strong family history of gastrointestinal cancers
Clinical Indications for Testing
Healthcare providers typically recommend this test when patients demonstrate clinical features suggestive of hereditary cancer syndromes, including Amsterdam criteria or revised Bethesda guidelines for Lynch syndrome identification.
Significant Benefits of Genetic Cancer Screening
Proactive Health Management
Undergoing MLH3 genetic testing provides numerous advantages for your long-term health:
- Early Risk Identification: Detect genetic predisposition before cancer develops
- Personalized Screening Protocols: Tailor colonoscopy frequency based on genetic risk
- Family Health Planning: Inform relatives about potential inherited cancer risks
- Preventive Strategies: Implement lifestyle modifications and surveillance measures
- Treatment Guidance: Inform therapeutic decisions if cancer does develop
- Peace of Mind: Reduce uncertainty about hereditary cancer risks
Understanding Your Test Results
Interpreting Genetic Findings
Your test results will fall into one of several categories, each with specific implications:
- Positive Result: Indicates the presence of a pathogenic MLH3 variant. This suggests increased cancer risk and warrants enhanced surveillance and preventive measures.
- Negative Result: No known pathogenic variants detected. However, this doesn’t eliminate all cancer risk, as other genetic or environmental factors may contribute.
- Variant of Uncertain Significance (VUS): Identifies a genetic change with unknown clinical significance. Ongoing research may clarify these findings over time.
- Benign Variants: Common genetic variations not associated with increased cancer risk.
Post-Test Recommendations
All positive results and VUS findings should be discussed with a genetic counselor or oncology specialist who can provide personalized recommendations for surveillance, prevention, and family testing.
Test Details and Pricing
| Test Component | Details |
|---|---|
| Test Name | MLH3 Gene Colorectal Cancer Hereditary Nonpolyposis Type 7 NGS Genetic DNA Test |
| Regular Price | $700 USD |
| Discount Price | $500 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) Technology |
| Specialty | Oncology Genetics |
Pre-Test Requirements and Preparation
Before undergoing testing, we recommend:
- Comprehensive clinical history documentation
- Genetic counseling session to discuss implications and expectations
- Development of detailed family pedigree chart
- Informed consent process explaining potential outcomes
- Discussion of insurance coverage and potential implications
Nationwide Accessibility
GGC DNA maintains testing facilities across the United States, with convenient locations in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, and many other cities. Our network ensures that quality genetic testing is accessible to patients nationwide.
Take Control of Your Genetic Health Today
Don’t leave your cancer risk to chance. The MLH3 Gene Colorectal Cancer Hereditary Nonpolyposis Type 7 NGS Genetic DNA Test provides the critical information needed to make informed decisions about your health and your family’s future. With our discounted price of $500 USD and comprehensive genetic analysis, you’re investing in peace of mind and proactive healthcare.
Ready to schedule your genetic cancer screening? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Our team is available to answer your questions and guide you through the testing process with compassion and expertise.
Take the first step toward understanding your genetic cancer risk – your future self will thank you.
